Quidel
This article was originally published in The Gray Sheet
Executive Summary
Debt holder Amoco Technology Company converts a 7.9% note for $2.4 mil. plus $658,839 in interest into 428,532 shares of Quidel common stock at a $7.14 per share conversion price. The note was issued in 1990 and "would have become convertible at the option of Quidel in August of this year at the same conversion price," according to Quidel. The maker of rapid diagnostic tests announced the retirement of $4 mil. in 12% unsecured long-term debt earlier this month ("The Gray Sheet" July 19, p. 22). The firm says the two transactions increase shareholder equity by 72% over the March 31 level.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.